Tardive dyskinesia (TD) is one of the most significant side
|
|
- Alexis Copeland
- 5 years ago
- Views:
Transcription
1 Brief Communication Diabetes, Tardive Dyskinesia, Parkinsonism, and Akathisia in Schizophrenia: A Retrospective Study Applying 1998 Diabetes Health Care Guidelines to Antipsychotic Use Emmanuelle Lévy, MD, FRCPC 1, Howard C Margolese, MD, CM, FRCPC 2, Lawrence Annable, BSc, DipStat 3, Guy Chouinard, MD, MSc, FRCPC 4 Background: This study examines the links among diabetes, tardive dyskinesia (TD), and other extrapyramidal symptoms (EPS) in schizophrenia outpatients treated with typical and atypical antipsychotics. Objectives: Using a retrospective chart review, we compared 30 schizophrenia patients with diabetes mellitus (DM) with 30 schizophrenia patients, matched for age and sex, with no DM. We compared prevalence and severity of parkinsonism, akathisia, TD, dystonia, and antipsychotic type (that is, typical vs atypical). Results: We found no statistically significant differences between the DM group and the non-dm group prevalence and severity of EPS, including TD. Conclusion: We did not find DM and TD association to be significant in the era of atypical antipsychotics, possibly because of their antidyskinetic effect. (Can J Psychiatry 2004;49: ) Information on author affiliations appears at the end of the article. Clinical Implications Diabetes mellitus (DM) may no longer be associated with tardive dyskinesia, because extrapyramidal symptoms (EPS) are alleviated by atypical antipsychotics. Because atypical antipsychotics are associated with a higher incidence of DM, psychiatrists should be aware of DM treatment, particularly for schizophrenia patients who are reluctant to consult other physicians. We review the treatment strategies for DM and the use of antipsychotics. Limitations The small sample size may limit the generalization of our results. The precision of our data may have been compromised by the retrospective chart review design. There is a lack of uniformity between the time at which the EPS were evaluated and the latest antipsychotic medication was prescribed. Tardive dyskinesia (TD) is one of the most significant side effects of classical antipsychotics (CAPs). Patient-related factors associated with TD include age, sex, psychiatric diagnosis, extrapyramidal symptoms (EPS), cognitive deficits, and structural brain damage (1,2). Diabetes mellitus (DM) Key Words: antipsychotics, neuroleptics, diabetes mellitus, akathisia, dystonia, tardive dyskinesia, extrapyramidal symptoms may also be a risk factor for TD (1,2). Mukherjee and colleagues suggested a possible association between TD and impaired glucose metabolism (3,4). Other studies report a higher incidence of DM in relatives of patients with TD, suggesting a genetic link between dopamine mechanisms and 398
2 Diabetes, Tardive Dyskinesia, Parkinsonism, and Akathisia in Schizophrenia Table 1 Demographic and clinical characteristics of schizophrenia patients with and without diabetes mellitus glucose regulation (5). Schultz and colleagues suggested that hyperinsulinemia and hyperglycemia associated with insulin resistance contribute to TD pathogenesis (6). In contrast, 2 studies failed to replicate the correlation between TD and DM (7,8). Therefore, the relation between DM and abnormal movements requires further empirical validation. This study hypothesized that antipsychotic (AP)-treated chronic schizophrenia patients with DM are more likely to develop abnormal movements than are patients with no DM. We also expected greater severity of abnormal movements in the DM group. Methods Study Procedure We conducted a retrospective chart review of 60 patients diagnosed with schizophrenia according to DSM-IV criteria. After obtaining approval from the McGill Research Ethics DM+ (n = 30) DM (n = 30) P Age (years) 55.9 (SD 11.6) 55.9 (SD 11.01) 0.99 Men (%) Women (%) Ethnicity (%) White Black Asian History of alcohol abuse (%) History of substance abuse (%) Prolactin level 25.2 (SD 24.5) 20.1 (SD 14.0) 0.30 ECT Number of patients Average number of ECT 4 30 Presence of brain damage (%) Typical AP prescribed (%) Duration of typical AP (months) 70.3 (SD 72.2) 62.2 (SD 69.7) 0.89 CPZ for typical AP (mg daily) (SD 556.3) (SD 462.9) 0.70 AAP prescribed (%) Duration of AAP (months) 27.2 (SD 35.6) 18.7 (SD 28.8) 0.50 CPZ for AAP (mg daily) (SD 495.5) (SD 405.0) Patients using anticholinergics (%) AAP = atypical antipsychotic; AP = Antipsychotic; CPZ = chlorpromazine; DM+ = with diabetes mellitus; DM = with no diabetes mellitus; therapy; ECT = electroconvulsive 0.07 Board, we examined the charts of patients from the outpatient special follow-up (SFU) clinic for schizophrenia, McGill University Health Centre (MUHC). We included patients aged 18 to 65 years who were prescribed APs and who had a DSM-IV diagnosis of schizophrenia and DM, according to 1998 guidelines (9). We identified 35 out of 300 schizophrenia patients attending the SFU clinic with DM type 1 or type 2. To form the control group, we matched for age and sex 30 schizophrenia patients from SFU with DM and 30 schizophrenia patients from SFU with no DM. We excluded the remaining 5 patients because no matched control subjects were found. We obtained the following information from the patients charts: age; sex; ethnicity; DM status, type, and duration; dosage and interval of AP treatment; psychiatric diagnosis; past or present substance use; history of electroconvulsive therapy (ECT); and brain damage. We collected laboratory investigations completed within the last year, including prolactin, random glucose, hemoglobin A 1C, and lipid profile. We also recorded other medication use, including anticholinergics, antiepileptics, antidepressants, benzodiazepines, and oral antihyperglycemics. We evaluated EPS, including parkinsonism, TD, akathisia, and dystonia, using the Extrapyramidal Symptom Rating Scale (ESRS) (10). The ESRS is conducted at least yearly on SFU patients, and results are recorded in their charts. To establish EPS prevalence, a score of 3 or more on at least 1 ESRS item or a score of 2 on 2 items was required. We used the same cut-off scores to define presence or absence of TD, parkinsonism, and dystonia. Akathisia score was derived from the combined subjective and objective akathisia measures, where a total score of 3 or more on the 2 items indicated presence of akathisia. We identified patients as having DM, using 1 of 3 methods: 1) the patient was diagnosed by an endocrinologist in the MUHC metabolic clinic; 2) the patient was currently Can J Psychiatry, Vol 49, No 6, June
3 The Canadian Journal of Psychiatry Brief Communication Table 2 Prevalence of extrapyramidal symptoms as measured by the extraypyramidal symptoms rating scale (ESRS) DM+ (%) DM (%) P Parkinsonism Tardive dyskinesia Dystonia Akathisia EPS total DM+ = with diabetes mellitus; DM = with no diabetes mellitus; EPS = extrapyramidal symptoms Table 3 Severity of extrapyramidal symptoms as measured by the ESRS DM+ Mean (SD) DM Mean (SD) Parkinsonism 7.33 (5.16) 6.60 (5.74) 0.64 Tardive dyskinesia 4.12 (4.41) 5.88 (6.39) 0.11 Dystonia 0.63 (1.61) 0.8 (1.95) 0.74 Akathisia 0.3 (0.6) 0.85 (1.31) 0.06 EPS total (7.47) (11.71) 0.61 receiving hypoglycemics, metformin, and (or) glyburide; or 3) a fasting plasma glucose (FPG) blood test of more than 7 mmol/l was found at the SFU annual laboratory investigations. Statistical Analysis Regarding ESRS severity scores, we used paired t tests to compare DM patients and matched non-dm patients. We used McNemar s chi-square test for matched samples to investigate differences between patients with DM and patients with no DM regarding EPS, parkinsonism, akathisia, TD, and dystonia prevalence. We also compared CAP and atypical antipsychotic use. Results The mean age of our sample was 55.9 years (SD 11.3 years), and 70% were men. DM groups and non-dm groups did not differ significantly (P > 0.05) regarding age, sex, ethnicity, typical and atypical antipsychotic use, mean dosage (that is, chlorpromazine equivalents), treatment duration, anticholinergic use, prolactin level, history of ECT, brain damage, or past or present substance use (see Table 1). There were no statistically significant (P > 0.05) differences between patients with DM and patients with no DM regarding overall prevalence of EPS, parkinsonism, akathisia, TD, or dystonia, as measured on ESRS subscales (Table 2). Further, no statistically significant differences (P > 0.05) were found between patients with DM and patients with no DM in the P severity scores for total EPS, parkinsonism, akathisia, TD, or dystonia (Table 3). Discussion Previous studies report DM as a risk factor for TD. Ganzini and colleagues found 79% TD prevalence in 38 AP-treated patients with DM, compared with 53% in 38 matched control patients with no DM (P < 0.001) (1). Significantly higher TD severity was also found in the DM group (P < 0.001). However, a high prevalence (21%) of spontaneous dyskinesia was found in a DM group not treated with APs, suggesting that dyskinesia linked to DM might be mistaken for TD (1). Among 160 elderly patients beginning APs, Woerner and colleagues reported TD in 54.1% of DM type 2 patients and 25.6% of non-dm patients after 43 weeks of CAP exposure (P = 0.07) (2). After controlling for age and sex, TD risk among patients with DM was stronger (risk ratio 2.38; 95%CI, 1.04 to 5.46) (2). Schultz and others found a significant correlation (P < 0.006) between Abnormal Involuntary Movement Scale severity and baseline glucose measurements when controlling for age in 21 schizophrenia patients (6). These studies suggest higher prevalence and severity of TD in DM patients treated with CAPs. Two studies failed to replicate these findings. In a prospective study, 266 elderly patients were exposed to CAPs for a median 21 days (4). The 41 patients with DM did not display significantly more TD than did 225 patients with no DM, despite the vulnerability of this age group to movement disorders. However, this study did not use atypical antipsychotics. In a retrospective study, Raja and Azzoni compared 34 schiophrenia patients with DM and 34 schizophrenia patients without DM. TD prevalence in DM patients (33.3%) was not significantly different from that in patients with no DM (40%). However, only some patients (that is, 70% of DM patients and 44% of non-dm patients) were treated with APs for more than 3 months. Further, the authors omitted stating whether APs were classical or atypical. Finally, unlike our study, the relation between TD and EPS severity and DM was not explored. Nevertheless, the authors concluded that diabetes was unlikely to play a major role in the pathogenesis of TD (8; p 61). In this study, we did not replicate an association between DM and abnormal movements, which supports the findings of the 2 aforementioned studies (7,8). Contrary to our hypothesis, rates of EPS, including TD in patients with DM, were similar to those in patients with no DM. In our sample, there was a nonsignificant trend toward more patients in the DM (67%) vs non-dm group (53%) being 400
4 Diabetes, Tardive Dyskinesia, Parkinsonism, and Akathisia in Schizophrenia prescribed atypical antipsychotics. This suggests that lower prevalence of TD in the DM group might be explained by the antidyskinetic effect of atypical antipsychotics (11 13). Because prior AP use was not always documented, calculations of cumulative APs are rendered uncertain a consistent limitation in TD studies. Because of known noncompliance in schizophrenia patients, accuracy of assessing cumulative AP exposure, dosage, or concurrent use of other medications, including anticholinergics, which may alter TD rates (14), is limited. This is the case with all studies using cumulative AP exposure. Another limitation is the lack of uniformity between time of ESRS evaluations and the latest medication prescription: some ESRS ratings are dated up to 1 year prior to the latest prescription. The small sample size, yielding low statistical power, may have prevented our finding an association between DM and TD. Given that atypical antipsychotics are also associated with a higher incidence of DM (15 19), it is important for psychiatrists to be aware of DM treatment, particularly for schizophrenia patients who are reluctant to consult other physicians. The 1998 Clinical Practice Guidelines for the Management of Diabetes in Canada (9) recommend measuring FPG annually if DM risk factors are present. Risk factors include family history of DM, ethnicity, obesity, coronary artery disease, hypertension, history of impaired glucose tolerance (that is, FPG < 7 mmol/l), impaired fasting glucose (that is, 6.1 < FPG < 6.9), low high-density lipoprotein cholesterol levels ( 0.9 mmol/l), or high fasting triglycerides levels (> 2.8 mmol/l) (9). Nutritional counselling, diet, exercise, and behavioural modification should first be addressed when patients using atypical anitpsychotics display more than 1 risk factor. If DM type 2 is diagnosed, lifestyle changes and smoking avoidance should be addressed. If adequate glucose levels are not achieved within 2 to 4 months, lifestyle changes should be reviewed and an oral hypoglycemic agent in monotherapy should be added. Sulfonylurea or biguanides are recommended if FPG > 10 mmol/l. Biguanides (metformin) are preferable when used with atypical antipsychotics because biguanides are associated with less weight gain. However, biguanides remain contraindicated with renal or hepatic insufficiency. If adequate glucose levels are not achieved within 2 to 4 months, even after maximizing dosage, combination oral hypoglycemics should be considered. Bedtime insulin with oral agents is reserved for patients not responding to lifestyle modifications and oral combination therapy (9). In conclusion, our results suggest that the association between DM and TD may no longer be significant in the era of atypical antipsychotics. Prospective studies are needed to corroborate these findings. Although the prevention of DM is an important issue with atypical antipsychotics, it does not appear to be a contributing factor of TD. References 1. Ganzini L, Heintz RT, Hoffman WF, Casey DE. The prevalence of tardive dyskinesia in neuroleptic-treated diabetics. A controlled study. Arch Gen Psychiatry 1991;48: Woerner MG, Saltz BL, Kane JM, Lieberman JA, Alvir JM. Diabetes and development of tardive dyskinesia. Am J Psychiatry 1993;150: Mukherjee S, Wisniewski A, Bilder R, Sackeim HA. Possible association between tardive dyskinesia and altered carbohydrate metabolism. Arch Gen Psychiatry 1985;42: Mukherjee S, Roth SD, Sandyk R, Schnur DB. Persistent tardive dyskinesia and neuroleptic effects on glucose tolerance. Psychiatry Res 1989;29: Mukherjee S, Mahadik S. Diabetes mellitus and tardive dyskinesia. In: Yassa R, editor. Neuroleptic-induced movement disorders. New York: Cambridge University Press; Schultz SK, Arndt S, Ho BC, Oliver SE, Andreasen NC. Impaired glucose tolerance and abnormal movements in patients with schizophrenia. Am J Psychiatry 1999;156: Jeste DV, Caligiuri MP, Paulsen JS, Heaton RK, Lacro JP, Harris MJ, and others. Risk of tardive dyskinesia in older patients. A prospective longitudinal study of 266 outpatients. Arch Gen Psychiatry 1995;52: Raja M, Azzoni A. Diabetes is not a risk factor for tardive dyskinesia: a retrospective observational study. Human Psychopharmacol 2002;17: Meltzer S, Leiter L, Daneman D, Gerstein HC, Lau D, Ludwig S, and others clinical practice guidelines for the management of diabetes in Canada. Canadian Diabetes Association. CMAJ 1998;159 (Suppl 8):S1 S Chouinard G, Ross-Chouinard A, Annable L, Jones B. The extrapyramidal symptom rating scale. Can J Neurol Sci 1980;7: Chouinard G. Effects of risperidone in tardive dyskinesia: an analysis of the Canadian multicenter risperidone study. J Clin Psychopharmacol 1995;15:36S 44S. 12. Littrell KH, Johnson CG, Littrell S, Peabody CD. Marked reduction of tardive dyskinesia with olanzapine. Arch Gen Psychiatry 1998;55: Tamminga CA, Thaker GK, Moran M, Kakigi T, Gao XM. Clozapine in tardive dyskinesia: observations from human and animal model studies. J Clin Psychiatry 1994;55(Suppl B): Wszola BA, Newell KM, Sprague RL. Risk factors for tardive dyskinesia in a large population of youths and adults. Exp Clin Psychopharmacol 200;9: Sernyak MJ, Leslie DL, Alarcon RD, Losonczy MF, Rosenheck R. Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia. Am J Psychiatry 2002;159: Koller EA, Doraiswamy PM. Olanzapine-associated diabetes mellitus. Pharmacotherapy 2002;22: Koro CE, Fedder DO, L Italien GJ, Weiss S, Magder LS, Kreyenbuhl J, and others. An assessment of the independent effects of olanzapine and risperidone exposure on the risk of hyperlipidemia in schizophrenic patients. Arch Gen Psychiatry 2002;59: Sobel M, Jaggers ED, Franz MA. New-onset diabetes mellitus associated with the initiation of quetiapine treatment. J Clin Psychiatry 1999;60: Henderson DC, Cagliero E, Gray C, Nasrallah RA, Hayden DL, Schoenfeld DA, Goff DC. Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: a five-year naturalistic study. Am J Psychiatry 2000;157: Manuscript received June 2003, revised, and accepted December Clinical Research Fellow, Clinical Psychopharmacology Unit, McGill University Health Centre and Department of Psychiatry, McGill University, Montreal, Quebec. 2 Assistant Professor, Clinical Psychopharmacology Unit, McGill University Health Centre and Department of Psychiatry, McGill University, Montreal, Quebec. 3 Professor, Clinical Psychopharmacology Unit, McGill University Health Centre and Department of Psychiatry, McGill University, Montreal, Quebec. 4 Professor, Louis-H Lafontaine Hospital, Fernand-Séguin Research Centre, Department of Psychiatry, University of Montreal, Montreal, Quebec; Director, Clinical Psychopharmacology Unit, McGill University Health Centre and Department of Psychiatry, McGill University, Montreal, Quebec. Address for correspondence: Dr E Lévy, Clinical Psychopharmacology Unit, Allan Memorial Institute, McGill University Health Centre, 1025 Pine Avenue W, Montreal, QC H3A 1A1 psychopharm.unit@mcgill.ca Can J Psychiatry, Vol 49, No 6, June
5 The Canadian Journal of Psychiatry Brief Communication Résumé : Le diabète, la dyskinésie tardive, le parkinsonisme et l acathisie dans la schizophrénie : une étude rétrospective Contexte : Cette étude examine la relation entre le diabète et la dyskinésie tardive (DT) et d autres symptômes extrapyramidaux (SEP) chez les patients schizophrènes externes traités aux antipsychotiques typiques et atypiques. Objectifs : À l aide d un examen rétrospectif des dossiers, nous avons comparé 30 patients schizophrènes souffrant de diabète assortis selon l âge et le sexe avec 30 patients schizophrènes ne souffrant pas de diabète. Nous avons comparé la prévalence et la gravité du parkinsonisme, de l acathisie, de la DT, de la dystonie et du type antipsychotique (soit typique ou atypique). Résultats : Nous n avons constaté aucune différence statistiquement significative entre les groupes diabétique et non diabétique en ce qui concerne la prévalence et la gravité des SEP, y compris la DT. Conclusion : Nous n avons pas trouvé que l association entre le diabète sucré et la DT était significative à l ère des antipsychotiques atypiques, peut-être à cause de leur effet antidyskinétique. 402
Use of Psychotherapeutic Medications in Children and Adolescents with ASD and ID
Use of Psychotherapeutic Medications in Children and Adolescents with ASD and ID Although not considered first line treatment in children with ASD and ID, depending on the severity of symptoms, some medications
More informationChapter 1.4. Intermittent neuroleptic treatment is a risk factor for tardive dyskinesia
Intermittent neuroleptic treatment is a risk factor for tardive dyskinesia The Curaçao Extrapyramidal Syndromes Study: III. Peter N. van Harten (1,3), Hans W. Hoek (2), Glenn E. Matroos (3), Maarten Koeter
More informationPharmacotherapy of psychosis and schizophrenia in youth
Pharmacotherapy of psychosis and schizophrenia in youth Benedetto Vitiello Pavia, 2 December 2017 Disclosure Benedetto Vitiello, M.D. Professor of Child and Adolescent Neuropsychiatry University of Turin,
More informationPsychosis and Agitation in Dementia
Psychosis and Agitation in Dementia Dilip V. Jeste, MD Estelle & Edgar Levi Chair in Aging, Director, Stein Institute for Research on Aging, Distinguished Professor of Psychiatry & Neurosciences, University
More informationMedication Audit Checklist- Antipsychotics - Atypical
Medication Audit checklist Page 1 of 7 10-2018 Audit number: Client number: Ordering Provider: INDICATIONS 1) Disorders with psychotic symptoms (schizophrenia, schizoaffective disorder, manic disorders,
More information1. The metabolic syndrome, syndrome X or the insulin Resistance Syndrome
Metabolic Side Effects and Management 1. The metabolic syndrome, syndrome X or the insulin Resistance Syndrome These terms refer to a syndrome consisting of central obesity as indicated by excessive visceral
More informationRecent Advances in the Antipsychotic Treatment of People with schizophrenia. Robert W. Buchanan, M.D.
Recent Advances in the Antipsychotic Treatment of People with schizophrenia Robert W. Buchanan, M.D. Antipsychotic medications are the primary class of drugs used in the pharmacological treatment of schizophrenia.
More informationLipid profile in antipsychotic drug users: A comparative study. Original Article
Lipid profile in antipsychotic drug users: A comparative study Hamidreza Roohafza (1), Azam Khani (2), Hamid Afshar (3), Mohammad Garakyaraghi (4), Afshin Amirpour (5), Basir Ghodsi (6) Abstract Original
More informationQuetiapine is a dibenzothiapine derivative that interacts
0271-0749/02/2204-0347/0 Journal of Clinical Psychopharmacology Vol. 22, No. 4 Copyright 2002 by Lippincott Williams & Wilkins, Inc. Printed in U.S.A. Therapeutic Tolerance and Rebound Psychosis During
More informationTreatment of Schizophrenia
Treatment of Schizophrenia Conduct comprehensive assessment and use measurement-based care as found in the Principles of Practice (review pages 4-7). Most importantly assess social support system (housing,
More informationProspective Study of Tardive Dyskinesia in the Elderly: Rates and Risk Factors
Prospective Study of Tardive Dyskinesia in the Elderly: Rates and Risk Factors Margaret G. Woerner, Ph.D., Jose Ma. J. Alvir, Dr.P.H., Bruce L. Saltz, M.D., Jeffrey A. Lieberman, M.D., and John M. Kane,
More informationOriginal Research. Dan Cooper, BPharm, MSc 1, Jocelyne Moisan, PhD 2, Michel Gaudet, MSc 3, Belkacem Abdous, PhD 4, Jean-Pierre Grégoire, MPH, PhD 5
Original Research Ambulatory Use of Olanzapine and Risperidone: A Population-Based Study on Persistence and the Use of Concomitant Therapy in the Treatment of Schizophrenia Dan Cooper, BPharm, MSc 1, Jocelyne
More informationCocaine is a Major Risk Factor for Antipsychotic Induced Akathisia, Parkinsonism and Dyskinesia By Arija Maat, Annemarie Fouwels, Lieuwe de Haan
PB-41-3-2008-De haan.qxp 09-09-2008 15:45 Page 5 ORIGINAL RESEARCH Key Words: cannabis, cocaine, drug abuse, extrapyramidal side effects, neuroleptics, antipsychotics Cocaine is a Major Risk Factor for
More informationMinimising the Impact of Medication on Physical Health in Schizophrenia
Minimising the Impact of Medication on Physical Health in Schizophrenia John Donoghue Liverpool Imagination is more important than knowledge Albert Einstein LIFESTYLE Making choices TREATMENT Worse Psychopathology,
More informationAtypical Antipsychotics and the Risk of Diabetes in an Elderly Population in Long-Term Care: A Retrospective Nursing Home Chart Review Study
Atypical Antipsychotics and the Risk of Diabetes in an Elderly Population in Long-Term Care: A Retrospective Nursing Home Chart Review Study Stewart G. Albert, MD, George T. Grossberg, MD, Papan J. Thaipisuttikul,
More informationSwitching antipsychotics: Basing practice on pharmacology & pharmacokinetics
Switching antipsychotics: Basing practice on pharmacology & pharmacokinetics John Donoghue Liverpool L imagination est plus important que le savoir Albert Einstein Switching Antipsychotics: Objectives
More informationPRESCRIBING GUIDELINES
The Maudsley The South London and Maudsley NHS Foundation Trust & Oxleas NHS Foundation Trust PRESCRIBING GUIDELINES 10th Edition David Taylor Carol Paton Shitij Kapur informa healthcare Contents Authors
More informationI received help from Bosch Health Care
John Kasckow, MD, PhD VA Pittsburgh Health Care System Western Psychiatric Institute and Clinic, UPMC VA Pittsburgh Health Care System I received help from Bosch Health Care 1 Diagnoses of Interest Early
More informationThe Prevalence of Metabolic Syndrome in Schizophrenic Patients Using Antipsychotics
Original Article http://dx.doi.org/10.9758/cpn.2013.11.2.80 pissn 1738-1088 / eissn 2093-4327 Clinical Psychopharmacology and Neuroscience 2013;11(2):80-88 Copyrightc 2013, Korean College of Neuropsychopharmacology
More informationObjectives. Epidemiology. Diagnosis 3/27/2013. Identify positive and negative symptoms used for diagnosis of schizophrenia
Objectives Identify positive and negative symptoms used for diagnosis of schizophrenia Mohamed Sallout, Pharm D. Pharmacist Resident St. Luke s Magic Valley Regional Medical Center List medications used
More informationBuspar and tardive dyskinesia
Search Search Buspar and tardive dyskinesia 4-12-2017 Tardive dyskinesia is a sometimes-permanent side effect of antipsychotic medications. WebMD explains. Can BuSpar cause Tardive Dyskinesia? Tardive
More informationMore than We Bargained For: Metabolic Side Effects of Antipsychotic Medications
More than We Bargained For: Metabolic Side Effects of Antipsychotic Medications Michael D. Jibson, MD, PhD Professor of Psychiatry University of Michigan Disclosure In the past 12 months I have received
More informationAntipsychotic Medications
TRAIL: Team Review of EVIDENCE REVIEW & RECOMMENDATIONS FOR LTC Behavioural and psychological symptoms of dementia (BPSD) refer to the non-cognitive symptoms of disturbed perception, thought content, mood
More informationWeight Change During Diet and Exercise Interventions Among Overweight Adults with Type 2 Diabetes: Results of a Chart Review
weight change and interventions 255 original research Weight Change During Diet and Exercise Interventions Among Overweight Adults with Type 2 Diabetes: Results of a Chart Review Golyar Keyhan 1 MD FRCPC,
More informationThe 2009 Schizophrenia PORT Psychopharmacological Treatment Recommendations and Summary Statements
Schizophrenia Bulletin vol. 36 no. 1 pp. 71 93, 2010 doi:10.1093/schbul/sbp116 Advance Access publication on December 2, 2009 The 2009 Schizophrenia PORT Psychopharmacological Treatment Recommendations
More informationUC San Francisco UC San Francisco Previously Published Works
UC San Francisco UC San Francisco Previously Published Works Title Roles in and barriers to metabolic screening for people taking antipsychotic medications: A survey of psychiatrists Permalink https://escholarship.org/uc/item/6xh6w409
More informationWARNING LETTER DEPARTMENT OF HEALTH & HUMAN SERVICES TRANSMITTED BY FACSIMILE
DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration Rockville, MD 20857 TRANSMITTED BY FACSIMILE Ajit Shetty, M.D. CEO Janssen Pharmaceutica, Inc. 1125 Trenton-Harbourton
More informationThe Maudsley Prescribing Guidelines in
The Maudsley Prescribing Guidelines in 11th Edition David Taylor Director of Pharmacy and Pathology South London and Maudsley NHS Foundation Trust; Professor King's College London, London, UK Paton Chief
More informationSiGMA/ MMHSCT GUIDELINES FOR ANTIPSYCHOTIC DRUG TREATMENT OF SCHIZOPHRENIA. [compatible with NICE guidance]
SiGMA/ MMHSCT GUIDELINES FOR ANTIPSYCHOTIC DRUG TREATMENT OF SCHIZOPHRENIA [compatible with NICE guidance] Medicines Management Committee August 2002 For review August 2003 Rationale The SiGMA algorithm
More informationOptima Health. Schizophrenia. Next Review Date 9/19
Optima Health Schizophrenia Guideline History Original Approve Date 04/01 Review/Revise 3/05, 12/06, 09/08, 11/08, Dates 11/10, 7/11, 7/13, 7/15, 9/17 Next Review Date 9/19 These Guidelines are promulgated
More informationReviews and Overviews. Lower Risk for Tardive Dyskinesia Associated With Second-Generation Antipsychotics: A Systematic Review of 1-Year Studies
Reviews and Overviews Lower Risk for Tardive Dyskinesia Associated With Second-Generation Antipsychotics: A Systematic Review of 1-Year Studies Christoph U. Correll, M.D. Stefan Leucht, M.D. John M. Kane,
More informationMichael J. Bailey, M.D. OptumHealth Public Sector
Michael J. Bailey, M.D. OptumHealth Public Sector LIHP Quality Charter To ensure the quality of care delivered to enrollees in San Diego County Assistance Programs, such as County Medical Services (CMS)
More informationReviews and Overviews. Physical Health Monitoring of Patients With Schizophrenia
Reviews and Overviews Physical Health Monitoring of Patients With Schizophrenia Stephen R. Marder, M.D. Susan M. Essock, Ph.D. Alexander L. Miller, M.D. Robert W. Buchanan, M.D. Daniel E. Casey, M.D. John
More informationAntipsychotic Prescription Pattern among Child and Adolescent Patients with Psychiatric Illnesses in Taiwan
222 Taiwanese Journal of Psychiatry (Taipei) Vol. 31 No. 3 2017 Original Article Antipsychotic Prescription Pattern among Child and Adolescent Patients with Psychiatric Illnesses in Taiwan Shu-Wen Cheng,
More informationRETROSPECTIVE COHORT STUDIES TO ASSESS AND COMPARE THE RISK OF INCIDENT DIABETES MELLITUS AND HYPERLIPIDEMIA IN
RETROSPECTIVE COHORT STUDIES TO ASSESS AND COMPARE THE RISK OF INCIDENT DIABETES MELLITUS AND HYPERLIPIDEMIA IN RISPERIDONE- AND OLANZAPINE-TREATED LONG-TERM INPATIENTS OF A STATE PSYCHIATRIC HOSPITAL.
More informationSevere Diabetic Ketoacidosis Precipitated by an Atypical Antipsychotic Drug
Bahrain Medical Bulletin, Vol. 29, No.4, December 2007 Severe Diabetic Ketoacidosis Precipitated by an Atypical Antipsychotic Drug Mohammad Naeem Niazy, MRCP, FRCPI* Ghassan Baidas, MRCP, FRCPI* Thomas
More informationFL Medicaid Drug Therapy Management Program for Behavioral Health Monitoring for Safety and Quality
FL Medicaid Drug Therapy Management Program for Behavioral Health Monitoring for Safety and Quality April 23, 2014 Pensacola, FL Presentation Objectives To briefly describe the program and how its components
More informationSchizophrenia, a devastating chronic. Treatment Adherence Associated With Conventional and Atypical Antipsychotics in a Large State Medicaid Program
Treatment Adherence Associated With Conventional and Atypical Antipsychotics in a Large State Medicaid Program Joseph Menzin, Ph.D. Luke Boulanger, M.A. Mark Friedman, M.D. Joan Mackell, Ph.D. John R.
More informationDosing & Administration
Dosing & Administration REAL LIFE. REAL RESULTS. INDICATION INVEGA SUSTENNA (paliperidone palmitate) is indicated for the treatment of: Schizophrenia. Schizoaffective disorder as monotherapy and as an
More informationRole of Clozapine in Treatment-Resistant Schizophrenia
Disease Management and Treatment Strategies Elkis H, Meltzer HY (eds): Therapy-Resistant Schizophrenia. Adv Biol Psychiatry. Basel, Karger, 2010, vol 26, pp 114 128 Role of Clozapine in Treatment-Resistant
More informationAssessing Conformance to Medication Treatment Guidelines for Schizophrenia in a Community Mental Health Center (CMHC)
Community Mental Health Journal, Vol. 39, No. 6, December 2003 ( 2003) Assessing Conformance to Medication Treatment Guidelines for Schizophrenia in a Community Mental Health Center (CMHC) Mona Goldman,
More informationSHARED CARE GUIDELINE
SHARED CARE GUIDELINE Title: Shared Care Guideline for the prescribing and monitoring of Antipsychotics for the treatment of Schizophrenia and psychotic symptoms in children and adolescents Scope: Pennine
More informationIntroduction. Objectives. Psychotropic Medications & Cardiometabolic Risk
Psychotropic Medications & Cardiometabolic Risk Sam Ellis, PharmD, BCPS, CDE Associate Professor University of Colorado School of Pharmacy Introduction Second GenerationAntipsychotics (SGA) first FDA approved
More informationRUNNING HEAD: Efficacy, Long Acting Injectable Antipsychotics and Schizophrenia 1
RUNNING HEAD: Efficacy, Long Acting Injectable Antipsychotics and Schizophrenia 1 Efficacy of Long Acting Injectable Antipsychotics in Early Onset Schizophrenia Linda Pietras RN-BC Mercyhurst University
More informationChapter I.3. The inter-relationships of tardive dyskinesia, parkinsonism, akathisia and tardive dystonia
Chapter I.3 The inter-relationships of tardive dyskinesia, parkinsonism, akathisia and tardive dystonia The Curaçao Extrapyramidal Syndromes Study: II. Peter N. van Harten (1,3) Hans W. Hoek (2), Glenn
More informationClinical Guidelines for the Pharmacologic Treatment of Schizophrenia
Clinical Guidelines for the Pharmacologic Treatment of Community Behavioral Health (CBH) is committed to working with our provider partners to continuously improve the quality of behavioral healthcare
More informationAnti-psychotic Polypharmacy in the Treatment of Patients with Resistant Schizophrenia: A Descriptive Study
Research Reviews: Pharmacy & Pharmaceutical Sciences e-issn: 2320-1215 www.rroij.com Anti-psychotic Polypharmacy in the Treatment of Patients with Resistant Schizophrenia: A Descriptive Study Etwal Bou
More informationHearts and Minds An ECG Update. Tuesday 18 th November The Met Hotel, Leeds
Hearts and Minds An ECG Update Tuesday 18 th November The Met Hotel, Leeds Ashleigh Bradley Specialist Clinical Pharmacist for Mental Health and Lithium Clinic Airedale NHS Foundation Trust Introduction
More informationThe Scourge of EPS: Have Atypical Antipsychotics Solved the Problem? Copyright 2001 Physicians Postgraduate Press, Inc.
The Scourge of EPS: Have Atypical Antipsychotics Solved the Problem? T his ACADEMIC HIGHLIGHTS section of The Journal of Clinical Psychiatry summarizes the highlights of a symposium entitled Clear Vision
More informationUniversity of Groningen
University of Groningen A 12-month follow-up study of treating overweight schizophrenic patients with aripiprazole Schorr, S. G.; Slooff, C. J.; Postema, R.; Van Oven, W.; Schilthuis, M.; Bruggeman, Richard;
More informationTreatment of Children and Adolescents with Schizophrenia
Treatment of Children and Adolescents with Schizophrenia The evidence base pertaining to the pharmacotherapy of schizophrenia in children and adolescents (C&A) is tiny compared to what is available for
More informationDYSKINESIA IN INDIAN POPULATION
JPPS 2006; 3(1): 30 34 ORIGINAL ARTICLE A STUDY OF ANTIPSYCHOTIC INDUCED TARDIVE DYSKINESIA IN INDIAN POPULATION Gupta Ravi, Bhatia Manjeet S. ABSTRACT Objective: This study was aimed at, to assess the
More information) and serotonin Type 2 (5-HT 2A
Latuda (lurasidone HCl) Fact Sheet Schizophrenia FREQUENTLY ASKED QUESTIONS What type of patient with schizophrenia is appropriate for LATUDA? LATUDA is an atypical antipsychotic agent indicated for the
More informationMonitoring Metabolic Side Effects when Initiating Treatment with Second-Generation Antipsychotic Medication
Original Contributions Monitoring Metabolic Side Effects when Initiating Treatment with Second-Generation Antipsychotic Medication Ellen Weissman 1, Carlos Jackson 2, Nina Schooler 3, Ray Goetz 4, Susan
More informationInfluence of novel and conventional antipsychotic medication on subjective quality of life
Research Paper Article de recherche Return to March 2001 Table of Contents Influence of novel and conventional antipsychotic medication on subjective quality of life Raymond Tempier, MD, MSc; Nicole Pawliuk,
More informationPrescribing antipsychotics for children and adolescents
POMH-UK Topic 10a baseline report Prescribing antipsychotics for children and adolescents September 2010 Prepared by the Prescribing Observatory for Mental Health-UK for Coventry and Warwickshire Partnership
More informationSAFETY AND TOLERABILITY: HOW DO NEWER GENERATION ATYPICAL ANTIPSYCHOTICS COMPARE?
Psychiatric Quarterly, Vol. 73, No. 4, Winter 2002 ( C 2002) SAFETY AND TOLERABILITY: HOW DO NEWER GENERATION ATYPICAL ANTIPSYCHOTICS COMPARE? Rajiv Tandon, M.D. Previously, clinicians worked with antipsychotic
More informationFaculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia. Abstract
ORIGINAL PAPER Co-morbid Hypertension, Diabetes Mellitus or Dyslipidemia among Patients Prescribed with Second Generation Antipsychotic: A Comparison Study between Aripiprazole, Quetiapine and Clozapine
More informationPharmacotherapy is the foundation of effective treatment
ORIGINAL ARTICLES Incidence of New-Onset Diabetes Mellitus Among Patients Receiving Atypical Neuroleptics in the Treatment of Mental Illness Evidence From a Privately Insured Population Edward Alan Miller,
More informationIndividualising antipsychotic treatment for patients with schizophrenia John Donoghue Liverpool
Copyright John Donoghue 2015 Individualising antipsychotic treatment for patients with schizophrenia John Donoghue Liverpool Copyright John Donoghue 2015 QUESTIONS Why do outcomes in schizophrenia remain
More informationChapter 17. Psychoses. Classifications of Psychoses. Schizophrenia. Factors Attributed to Development of Psychoses
Chapter 17 Psychoses Drugs for Psychoses Delusions Hallucinations Illusions Paranoia Upper Saddle River, New Jersey 07458 All rights reserved. Classifications of Psychoses Acute episode Chronic episode
More informationAntipsychotic-Related Risk for Weight Gain and Metabolic Abnormalities During Development Christoph U. Correll, MD
Antipsychotic-Related Risk for Weight Gain and Metabolic Abnormalities During Development Christoph U. Correll, MD Professor of Psychiatry and Molecular Medicine Hofstra North Shore - LIJ School of Medicine
More informationSHARED CARE GUIDELINE
SHARED CARE GUIDELINE Shared Care Guideline for the prescribing and monitoring of antipsychotics for the treatment of Neurodevelopmental Disorders in children and adolescents. Scope: Version 1 Pennine
More informationUNDERSTANDING AND MANAGING METABOLIC SYNDROME IN PSYCHIATRY Dr Sanil Rege MBBS, MRCPsych, FRANZCP Consultation-Liaison Psychiatry PaRK MHS, Western
UNDERSTANDING AND MANAGING METABOLIC SYNDROME IN PSYCHIATRY Dr Sanil Rege MBBS, MRCPsych, FRANZCP Consultation-Liaison Psychiatry PaRK MHS, Western Australia Talks Facilitator of the CTF Exam Prep Course
More informationPatients with major mental illnesses such as schizophrenia
REPORTS Metabolic Syndrome and Mental Illness John W. Newcomer, MD Abstract Patients with mental illnesses such as schizophrenia and bipolar disorder have an increased prevalence of metabolic syndrome
More informationDiabetes, Diet and SMI: How can we make a difference?
Diabetes, Diet and SMI: How can we make a difference? Dr. Adrian Heald Consultant in Endocrinology and Diabetes Leighton Hospital, Crewe and Macclesfield Research Fellow, Manchester University Relative
More informationUniversity of Groningen. Metabolic risk in people with psychotic disorders Bruins, Jojanneke
University of Groningen Metabolic risk in people with psychotic disorders Bruins, Jojanneke IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
More informationCurrent. Late-onset schizophrenia Make the right. diagnosis when psychosis emerges after age 60. p SYCHIATRY. New evidence shows psychosis
Late-onset schizophrenia Make the right diagnosis when psychosis emerges after age 60 Dan I. Lubman, PhD Senior research fellow and consultant psychiatrist David J. Castle, MD Professorial fellow University
More informationEffect of advanced access scheduling on chronic health care in a Canadian practice
Research Web exclusive Effect of advanced access scheduling on chronic health care in a Canadian practice Julie Gladstone MD Michelle Howard MSc PhD Abstract Objective To determine the effect of advanced
More informationDatix Ref:
Title Document Details Shared Care Agreement: Antipsychotics (Risperidone, Olanzapine, Quetiapine, Aripiprazole, Amisulpride or Asenapine) Trust Ref No 2081-38933 Local Ref (optional) Main points the document
More informationCambridge University Press Effective Treatments in Psychiatry Peter Tyrer and Kenneth R. Silk Excerpt More information
Organic disorders 1 Delirium Based on Delirium by Laura Gage and David K. Conn in Effective Treatments in Psychiatry, Cambridge University Press, 2008 Introduction Delirium needs treatment for both its
More informationIOWA MEDICAID DRUG UTILIZATION REVIEW COMMISSION 100 Army Post Road (515)
IOWA MEDICAID DRUG UTILIZATION REVIEW COMMISSION 100 Army Post Road (515) 974-3131 -866-626-0216 Brett Faine, Pharm.D. Larry Ambroson, R.Ph. Casey Clor, M.D. Professional Staff: Mark Graber, M.D., FACEP
More informationRISK FACTORS FOR TARDIVE DYSKINESIA AMONG ASIAN PATIENTS WITH SCHIZOPRHENIA. CHONG SIOW ANN MBBS, M.Med (Psychiatry), FAMS
RISK FACTORS FOR TARDIVE DYSKINESIA AMONG ASIAN PATIENTS WITH SCHIZOPRHENIA CHONG SIOW ANN MBBS, M.Med (Psychiatry), FAMS A THESIS SUBMITTED FOR THE DEGREE OF DOCTOR OF MEDICINE DEPARTMENT OF PHARMACOLOGY
More informationTreatment of Schizophrenia Appendix Three Page 1 of 8
Prescribing Guidelines Treatment of Schizophrenia Scope of this guidance This guidance aims to describe the pharmacological management of schizophrenia at a simple and intermediate level, with a brief
More informationDouglas Leslie, Ph.D.
Douglas Leslie, Ph.D. All Publications 1. Beam-Goulet J, Rosenheck RA and Leslie DL. Effectiveness of a Targeted Mailing Outreach Program on Supplemental Security Income Applications and Awards. Social
More informationDiabetes: Staying Two Steps Ahead. The prevalence of diabetes is increasing. What causes Type 2 diabetes?
Focus on CME at the University of University Manitoba of Manitoba : Staying Two Steps Ahead By Shagufta Khan, MD; and Liam J. Murphy, MD The prevalence of diabetes is increasing worldwide and will double
More informationTHIOTHIXENE. THERAPEUTICS Brands Navane see index for additional brand names. Generic? Yes
THIOTHIXENE THERAPEUTICS Brands Navane see index for additional brand names Generic? Yes Class Conventional antipsychotic (neuroleptic, thioxanthene, dopamine 2 antagonist) Commonly Prescribed for (bold
More informationClozapine and Polycythemia Rubra Vera: A Rare Side Effect or a Separate Medical Condition? A Case Report
CASE REPORT Clozapine and Polycythemia Rubra Vera: A Rare Side Effect or a Separate Medical Condition? A Case Report Tan HPJ Hospital Sentosa, Kuching, Sarawak, Malaysia Abstract This article highlights
More informationLevomepromazine versus chlorpromazine in treatment-resistant schizophrenia: a double-blind randomized trial
Research Paper Article de recherche versus chlorpromazine in treatment-resistant schizophrenia: a double-blind randomized trial Samarthji Lal, MD; Joseph X. Thavundayil, MD; N.P. Vasavan Nair, MD; Lawrence
More informationRe: Safety data on Zyprexa (olanzapine) and Symbyax (olanzapine and fluoxetine HCl capsules) Hyperglycemia, Weight Gain, and Hyperlipidemia
www.lilly.com Eli Lilly and Company Lilly Corporate Center Indianapolis, Indiana 46285 U.S.A. Phone 317 276 2000 October 5, 2007 Re: Safety data on Zyprexa (olanzapine) and Symbyax (olanzapine and fluoxetine
More informationMany patients with schizophrenia
Long-Term Antipsychotic Polypharmacy in the VA Health System: Patient Characteristics and Treatment Patterns Julie A. Kreyenbuhl, Pharm.D., Ph.D. Marcia Valenstein, M.D., M.S. John F. McCarthy, Ph.D.,
More informationPractical Psychopharmacology for More Complex Mental Health Presentations
MINISTRY OF CHILDREN AND YOUTH SERVICES Practical Psychopharmacology for More Complex Mental Health Presentations Part 2: Antipsychotics & Mood Stabilizers Dr. Ajit Ninan & Joel Lamoure 1 : Who are we?
More informationAppropriate Antipsychotic Treatment Selection in Early Phase Psychosis CPA 2017
Appropriate Antipsychotic Treatment Selection in Early Phase Psychosis CPA 2017 Presenters Marc-André Roy, MD, FRCPC Associate Professor. Department of Psychiatry and Neurosciences, Université Laval and
More informationSECTION 9 : MANAGEMENT OF MOVEMENT DISORDERS AND EXTRAPYRAMIDAL SIDE EFFECTS
SECTION 9 : MANAGEMENT OF MOVEMENT DISORDERS AND EXTRAPYRAMIDAL SIDE EFFECTS Formulary and Prescribing Guidelines 9.1 Introduction Movement disorders and extrapyramidal side effects can manifest in the
More informationESSENTIAL SHARED CAR E AGREEMENT FOR
E093 ESSENTIAL SHARED CARE AGREEMENT FOR Risperidone, Olanzapine, Quetiapine, Aripiprazole, or Amisulpride for Behavioural indications in People with Learning Disability (LD) Referral Criteria In some
More informationCHAPTER 3. Schizophrenia and Antipsychotic Treatment
CHAPTER 3 Schizophrenia and Antipsychotic Treatment What is it? It is a severe, chronic, disabling brain disease Considered to have biological origins but exact unknown 1% of population affected Schizophrenia
More informationDiabetes Mellitus Type 2 Evidence-Based Drivers
This module is supported by an unrestricted educational grant by Aventis Pharmaceuticals Education Center. Copyright 2003 1 Diabetes Mellitus Type 2 Evidence-Based Drivers Driver One: Reducing blood glucose
More informationTable of Contents. 1.0 Policy Statement...1
Division of Medical Assistance General Clinical Policy No. A-6 Table of Contents 1.0 Policy Statement...1 2.0 Policy Guidelines...1 2.1 Eligible Recipients...1 2.1.1 General Provisions...1 2.1.2 EPSDT
More informationVCU Scholars Compass. Virginia Commonwealth University. Della Varghese Virginia Commonwealth University
Virginia Commonwealth University VCU Scholars Compass Theses and Dissertations Graduate School 2013 Prevalence of Anti-diabetic and Antilipidemic Medications in Children and Adolescents treated with Atypical
More informationIs Aristada (Aripiprazole Lauroxil) a Safe and Effective Treatment For Schizophrenia In Adult Patients?
Philadelphia College of Osteopathic Medicine DigitalCommons@PCOM PCOM Physician Assistant Studies Student Scholarship Student Dissertations, Theses and Papers 12-2016 Is Aristada (Aripiprazole Lauroxil)
More informationIn recent years, reports of diabetes, diabetic
A REVIEW OF METABOLIC ISSUES IN ATYPICAL ANTIPSYCHOTIC TREATMENT John W. Newcomer, MD, * and Henry A. Nasrallah, MD ABSTRACT Reports of diabetes, diabetic ketoacidosis, hyperglycemia, and dyslipidemias
More informationTHERAPEUTIC AND EVOLUTIVE ASPECTS IN SCHIZOPHRENIA
UNIVERSITY OF MEDICINE AND PHARMACY OF CRAIOVA THERAPEUTIC AND EVOLUTIVE ASPECTS IN SCHIZOPHRENIA ABSTRACT Ph.D. Coordinator Professor Dragoș MARINESCU PhD Student: Mihai MUTICĂ Craiova 2016 TABLE OF CONTENTS
More informationIntroduction. J Mwanza 1, R Paul 1, JM Ncheka 1, P Petlovani 1. 1.University of Zambia School of Medicine, Department of Psychiatry
RESEARCH ARTICLE Appropriateness of antipsychotic drugs prescribed for First episode psychosis by clinicians at Chainama Hills college hospital in Lusaka J Mwanza 1, R Paul 1, JM Ncheka 1, P Petlovani
More informationAppendix D: Included Studies adverse effects review
DELIRIUM APPENDICES (Draft for Consultation) Appendix D: Included Studies adverse effects review Table D1: Studies directly comparing two antipsychotic agents in delirium Author Study design Setting Age
More informationThe Projection of Prevalence and Cost of Diabetes in Canada: 2000 to 2016
The Projection of Prevalence and Cost of Diabetes in Canada: to 2016 diabetes prevalence and cost in canada: 2016 1 Arto Ohinmaa 1,2 PhD, Philip Jacobs 1,2 PhD, Scot Simpson 1 PharmD MSc, Jeffrey A. Johnson
More informationComparative incidence of metabolic syndrome in patients with schizophrenia. being treated with second generation antipsychotics vs.
Comparative incidence of metabolic syndrome in patients with schizophrenia being treated with second generation antipsychotics vs. first generation antipsychotics: A Systematic Review of Literature By
More informationManaging Multiple Comorbidities in Bipolar Disorder
Available at CurrentPsychiatry.com/BipolarDepression A SUPPLEMENT TO This promotional, non-cme program is intended only for health care professionals involved in the treatment of adult patients with bipolar
More informationOutcomes and Costs of Risperidone versus Olanzapine in Patients with Chronic Schizophrenia or Schizoaffective Disorders: A Markov Model
Blackwell Science, LtdOxford, UKVHEValue in Health1098-30152004 Blackwell Publishing75569584Original ArticleOutcomes and Costs of Risperidone versus OlanzapineVera-Llonch et al. Volume 7 Number 5 2004
More informationCANadian Pediatric Weight management Registry CANPWR. UPDATE ON PROGRESS CANNeCTIN Meeting 27.April.2010
CANadian Pediatric Weight management Registry CANPWR UPDATE ON PROGRESS CANNeCTIN Meeting 27.April.2010 KM Morrison Hamilton (PI) Geoff Ball Edmonton, AB JP Chanoine Vancouver, BC Mark Tremblay Ottawa,
More informationMEDICAL ASSISTANCE HANDBOOK PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES. I. Requirements for Prior Authorization of Antipsychotics
MEDICAL ASSISTANCE HBOOK PRI AUTHIZATION OF PHARMACEUTICAL SERVICES I. Requirements for Prior Authorization of Antipsychotics A. Prescriptions That Require Prior Authorization Prescriptions for Antipsychotics
More information